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The in vitro activity of a series of ruthenium clusters, [(g6-C6H6)(g
6-C6Me6)2
Ru3(l-H)3(l3-O)][BF4], [(g
6-C6H6)(g
6-1,4-iPrC6H4Me)(g
6-C6Me6)Ru3(l-H)3(l3-
O)][BF4], [(g
6-C6H6)4Ru4(l-H)4][BF4]2, [(g
6-C6H5Me)4Ru4(l-H)4][BF4]2 and
[(g6-C6H6)4Ru4(l-H)3(l-OH)][Cl]2, has been evaluated against A2780 and
A2780cisR ovarian carcinoma cell lines. Both triruthenium clusters are very
active compared to ruthenium compounds in general, whereas the tetraruthenium
clusters do not display signiﬁcant cytotoxicities. Since the triruthenium clusters
are known to form supramolecular interactions with arenes and other functions,
it is possible that such interactions are also important with respect to their mode
of biological activity. The X-ray structure analysis of [(g6-C6H5Me)4Ru4
(l-H)4][PF6]2 is also reported.
KEY WORDS: Clusters; bioorganometallic chemistry; medicinal chemistry;
bioinorganic chemistry; ruthenium; in vitro assays; anticancer drugs.
INTRODUCTION
Recent years have witnessed a tremendous increase in research into
anticancer compounds based on ruthenium with two ruthenium coordina-
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tion compounds (Fig. 1) that have a diﬀerent spectrum of activity to
platinum drugs [1] currently undergoing clinical evaluation [2]. Notably, the
diﬀering activity is assigned to a diﬀerent mode of action guided by the high
aﬃnity of ruthenium(III) compounds toward proteins [3].
More recently, interest has focused on organometallic compounds [4],
speciﬁcally on ruthenium(II)-arene compounds, which show excellent
antiproliferative properties both in vitro and in vivo [5]. It has been found
that a structurally diverse range of compounds all exhibit interesting
properties. For example, a wide range of arenes can be tolerated and the
arene can even be replaced by cyclopentadienyl, pentamethylcyclopentadie-
nyl [6] or the sulphur macrocycle 1,4,7-trithiacyclononane without aﬀecting
the in vitro activity signiﬁcantly [7]. It has even been found that some
rhodium and osmium analogues, evaluated in HT29 colon carcinoma, A549
lung carcinoma and T47D breast carcinoma cell lines in vitro, display
activities that are not too dissimilar from the related ruthenium(II)-arene
complexes [8]. A feature of many of these compounds, notably those with
the 1,3,5-triaza-7-phosphatricyclo[3.3.1.1]decane (pta) ligand, is that
although the activity is lower than that of cisplatin and related Pt(II)
compounds in vitro, the activity against metastatic (secondary) tumours
evaluated in vivo is high in the absence of activity against the primary
cancers [9]. Furthermore, more cytotoxic agents can be prepared by
incorporating speciﬁc ligands of known biological function [10].
Metal clusters based on ruthenium, osmium and rhodium have been
shown to exhibit medicinal properties. In particular, it has been
postulated that the pharmacological properties of cluster complexes,
including Ru3(CO)9(pta)3, [Pt3(l3-CO)(l-dppm)3]
2+, HOs3(CO)9(l-L-H)L¢
[L = 3-amino quinoline, L¢ = P(C6H4SO3Na)3 or P(OCH2CH2NMe3I)3;
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Fig. 1 Clinically evaluated ruthenium-based anticancer drugs
742 Therrien et al.
L = 3-(2-phenylacetimido)-quinoline, L¢ = P(OCH2CH2NMe3I)3 or L =
phenanthridine, L¢ = P(OCH2CH2NMe3I)3] and Rh3(l3-S)2(g5-C5
Me5)3]
2+, are related to their ability to damage DNA, [11] although
enzyme inhibition could also be important [12]. While ruthenium-arene
complexes in which two ruthenium centres are bridged by a ligand have
received some attention, ruthenium-arene clusters with direct metal-metal
bonds have not been fully explored as potential anticancer agents.
Interest in clusters as anticancer agents also originated from the notion
that they could be rationally developed to target tumours speciﬁcally,
exploiting the enhanced permeability and retention’ (EPR) effect. The EPR
effect is a phenomenon in which macromolecules are able to accumulate at
the tumour site due to the dramatic increase in blood vessel permeability
within diseased tissues compared to normal tissues [13]. The normal
endothelial layer surrounding the blood vessels feeding healthy tissues is
intact, restricting the size of molecules that can diﬀuse from the blood. In
contrast, the endothelial layer of blood vessels in diseased tissues is more
porous to large molecules providing access to the surrounding tissue.
Furthermore, diseased tissue does not generally have a lymphatic drainage
system; hence once macromolecules have entered the tissue they are
retained. Notably, the cluster [(g6-C6H6)Ru4(l3-H)4]
2+ was even found to
be highly active against the polio virus without damaging the host cells,
thereby oﬀering the potential of developing it into a highly selective drug
[14].
Based on such nascent encouraging results we decided to evaluate a
series of triruthenium- and tetraruthenium-arene clusters for in vitro activity
evaluated against A2780 and A2780cisR ovarian carcinoma cell lines, the
latter being ca. 6-fold resistant to cisplatin treatment. The outcome of these
experiments is described herein.
RESULTS AND DISCUSSION
A series of ruthenium clusters with nuclearities of three and four,
speciﬁcally, [(g6-C6H6)(g
6-C6Me6)2Ru3(l-H)3(l3-O)][BF4] 1a, [15] [(g
6-
C6H6)(g
6-1,4-iPrC6H4Me)(g
6-C6Me6)Ru3(l-H)3(l3-O)][BF4] 1b, [16] [(g
6-
C6H6)4Ru4(l-H)4][BF4]2 2a [17], [(g
6-C6H5Me)4Ru4(l-H)4][BF4]2 2b and
[(g6-C6H6)4Ru4(l-H)3(l-OH)][Cl]2 2c [18] (see Chart 1) were prepared using
literature methods. Compound 2b is new and was isolated from the reaction
of [(g6-C6H5Me)Ru(l-Cl)Cl]2 in water with molecular hydrogen (55 atm,
60 C) which gives the tetranuclear hexahydrido cluster [(g6-C6H5Me)4
Ru4(l-H)6]
2+ that further reacts slowly with oxygen to form the tetrahydr-
ido cluster isolated as the tetraﬂuoroborate salt 2b.
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The 1H NMR spectrum of 2b in D2O gives, other than the aromatic
protons of the toluene ligands in the region 5.5–6.0 ppm and the
corresponding methyl signal at d = 2.1 ppm, a singlet hydride signal at
)17.7 ppm. The mass spectrum of [(g6-C6H5Me)4Ru4(l-H)4][BF4]2 exhibits
the [M + H]+ pseudomolecular ion peak m/z at 777.9.
The chloro or tetraﬂuoroborate salts of [(g6-C6H5Me)4Ru4(l3-H)4]
2+
did not yield single crystals that are of suﬃcient quality for X-ray diﬀraction
analyses. However, single crystals of the black hexaﬂuorophosphate salt
[(g6-C6H5Me)4Ru4(l3-H)4][PF6]2 were obtained via slow evaporation from
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Chart 1 Trinuclear (1a, 1b) and tetranuclear (2a-2c) ruthenium clusters evaluated for anti-
cancer activity in vitro
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a concentrated methanol solution. The ORTEP representation of the
dication [(g6-C6H5Me)4Ru4(l3-H)4]
2+ is shown in Fig. 2. Selected bond
lengths and angles are presented in Table 1 and compared to the geometrical
parameters of the analogous tetranuclear benzene derivative [(g6-
C6H6)4Ru4(l3-H)4][Cl]2 [17].
Table 1 Selected bond lengths (A˚) and angles () for [(g6-C6H5Me)4Ru4(l3-H)4][PF6]2
(cation of 2b) and [(g6-C6H6)4Ru4(l3-H)4][Cl]2 (cation of 2a)
[17]
[(g6-C6H5Me)4Ru4(l3-H)4][PF6]2 [(g
6-C6H6)4Ru4(l3-H)4][Cl]2
Ru–Ru (range) 2.667(1)–2.770(1) 2.729(2)–2.730(2)
Ru–Ru (mean) 2.724 2.730
Ru–C (range) 2.18(1)–2.28(1) 2.15(1)–2.23(1)
Ru–C (mean) 2.21 2.18
Ru–Ru–Ru (range) 57.86(3)–61.61(3) 59.96(2)–60.03(2)
Ru–Ru–Ru (mean) 59.23 60.02
Ru–H (mean) 1.79 2.02
Ru–H–Ru (mean) 100.4 81.4
C–CMe (range) 1.42(2)–1.52(2)
Fig. 2 ORTEP view of [(g6-C6H5Me)4Ru4(l3-H)4]
2+ (cation of 2b) with displacement ellip-
soids drawn at the 50% probability level; H-atoms and hexaﬂuorophosphate anions being
omitted for clarity
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The single-crystal X-ray structure analysis of [(g6-C6H5Me)4Ru4(l3-
H)4][PF6]2 indicates that the dication [(g
6-C6H5Me)4Ru4(l3-H)4]
2+ consist
of a tetranuclear ruthenium framework which co-ordinates four toluene
ligands. The four metal atoms form a slightly distorted tetrahedron with
Ru–Ru–Ru angles ranging from 57.86(3) to 61.61(3). The toluene ligands
are g6-bound to the ruthenium atom with an average Ru-C distance of
2.21 A˚, diﬀering only slightly from that observed in [(g6-C6H6)4Ru4(l3-
H)4][Cl]2 [2.18(1) A˚] [17]. The carbon atoms of the methyl groups are
displaced by less than 0.10(2) A˚ from the plane of the aromatic rings.
Unfortunately, the hydrido ligands could not be located from Fourier
diﬀerence map, and therefore ﬁxed as symmetrical l3-capped ligands above
the Ru3 triangles, as with other reported examples. In the crystal packing of
[(g6-C6H5Me)4Ru4(l3-H)4][PF6]2, the hexaﬂuorophosphate anions are inter-
calated between the cationic clusters and interact weakly with [(g6-
C6H5Me)4Ru4(l3-H)4]
2+ through multiple C–HÆÆÆF contacts; the CÆÆÆF
distances ranging from 3.16 to 3.56 A˚ and the C–HÆÆÆF angles from 119.4
to 169.6.
The ability of the compounds to inhibit cancer cell viability was
performed against two different ovarian cancer cell lines, A2780 and its
cisplatin-resistant strain A2780cisR, which exhibit a 6-fold increase in
cisplatin resistance. The effects of the clusters on the cancer cell growth were
evaluated after an exposure period of 72 h using the MTT [3-(4,5-
dimethylthiazol-2-yl))2,5-diphenyltetrazolium bromide] assay, which mea-
sures mitochondrial dehydrogenase activity as an indication of cell viability.
The IC50 values for the inhibition of cell viability of the complexes are listed
in Table 2. In addition, the dose-response curves for 1a and 1b against the
two cell lines are illustrated in Fig. 3.
From Table 2 it is clear that, while both the triruthenium clusters (1a
and 1b) are remarkably active in both cell lines, both being slightly less
active in the cisplatin-resistant A2780cisR cell line, the tetraruthenium
Table 2 Inhibition of cell viability (IC50) of complexes on A2780 and A2780cisR ovarian
carcinoma cell lines after 72 h of incubation, determined using MTT assay
Compounds A2780 A2780cisR
Cisplatin 1.5±0.3 8.7±1.6
RAPTA-C >100 >100
1a 9.8±0.2 14.6±0.7
1b 9.1±0.9 28.9±2.8
2a >100 >100
2b >100 >100
2c >100 >100
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clusters (2a–2c) are not cytotoxic. Although the values are about 3–6 times
higher than cisplatin, they are low in comparison to ruthenium-based
complexes, typically 20–30 times lower than the class of antimetastatic
ruthenium(II)-arene complexes containing the pta ligand (RAPTA-C). The
activities are also signiﬁcantly higher than organometallic ruthenium
complexes containing imidazolium, [19] dihydroxypyridyl, ferrocenyl and
polyoxomolybdenum clusters [20] screened for inhibition of cancer cell
growth ability against the same cell lines under similar condition. To date,
they are some of the most active ruthenium-cluster anticancer compounds
reported.
It is interesting to consider why the triruthenium clusters are highly
cytotoxic in comparison to the tetraruthenium clusters. The two classes of
clusters exhibit one major difference with respect to their chemical
reactivity; the triruthenium clusters present a hydrophobic pocket and a
l3-oxo ligand, which could form supramolecular interactions with arenes
and other functions, see Fig. 4. Indeed, the hydrophobic pocket spanned by
the three arene ligands can accommodate arene moieties [21], while the
l3-oxo ligand interacts strongly with hydroxyl groups [22]. By contrast, the
tetraruthenium clusters do not contain a hydrophobic pocket or a l3-oxo
ligand, and it is therefore tempting to attribute the cytotoxic activity of 1a
and 1b to a supramolecular recognition process within the cancer cell. Since
hydrophobic arene units and hydroxyl groups are usually buried inside
proteins, it is possible that a highly selective process is in operation. Clearly,
further experiments are required to prove such a hypothesis, but neverthe-
less, the correlation between the known supramolecular interactions of 1a
and 1b and their excellent activity in the ovarian cell lines is striking.
Fig. 3 Dose-response curves of exposure of compounds 1a (left) and 1b (right) to A2780
and A2780cisR ovarian carcinoma cell lines, determined using MTT assay
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EXPERIMENTAL
The compounds 1a, 1b, 2a, 2c were prepared according to literature
procedures [15–18]. The precursor [(g6-C6H5Me)Ru(l-Cl)Cl]2 was prepared
according to the published method [23]. The 1H NMR spectrum was
recorded using a Varian Gemini 200 MHz spectrometer. Microanalysis was
performed by the Laboratory of Pharmaceutical Chemistry, University of
Geneva (Switzerland). Electro-spray mass spectrum was obtained in
positive-ion mode with an LCQ Finnigan mass spectrometer.
Synthesis of [(g6-C6H5Me)4Ru4(l3-H)4][BF4]2 (2b)
A suspension of [(g6-C6H5Me)Ru(l-Cl)Cl]2 (158 mg, 0.3 mmol) in
H2O (20 ml) was hydrogenated in a stainless-steel autoclave at 60 C under
a pressure of 55 bar. After 24 h the autoclave was cooled, the pressure
released and the violet solution ﬁltered on celite. The water was removed
under reduced pressure and the violet residue dissolved in methanol (15 mL)
and stirred under air for 2 days. Evaporation of most of the solvent,
followed by precipitation at )10 C, gave the dichloride salt [(g6-
C6H5Me)4Ru4(l3-H)4][Cl]2 as a dark violet solid. Anion exchange is
performed in methanol with an excess of NaBF4 and precipitation at
)10 C to aﬀord the tetraﬂuoroborate salt [(g6-C6H5Me)4Ru4(l3-H)4][BF4]2
(80 mg, 56%). 1H NMR (200 MHz, D2O): d (ppm) = 6.01 (m, 3H) 5.57 (m,
2H) 2.12 (s, 3H) )17.71 (s, 1H). ESI-MS: m/z 777.90 [M + H]+. Elemental
analysis (%) calc. for C28H36B2F8Ru4: C, 35.38; H, 3.82 Found: C, 35.65; H,
4.01.
HRu
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Ru
Ru
RuO
H
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Fig. 4 Typical supramolecular interactions observed in 1 [23]
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Solid-State Structural Determination of [(g6-C6H5Me)4Ru4(l3-H)4][PF6]2
(cation of 2b)
Single crystals of [(g6-C6H5Me)4Ru4(l3-H)4][PF6]2 suitable for X-ray
diﬀraction analysis were obtained after addition of a small amount of KPF6
to a methanol solution containing [(g6-C6H5Me)4Ru4(l3-H)4][Cl]2. A crystal
of [(g6-C6H5Me)4Ru4(l3-H)4][PF6]2 was mounted on a Stoe Image Plate
Diﬀraction System equipped with a u circle goniometer, using Mo-Ka
graphite monochromated radiation (k = 0.71073 A˚) with u range 0–200,
increment of 1.2, Dmax)Dmin = 12.45–0.81 A˚. The structure was solved by
direct methods using the program SHELXS-97 [24]. The reﬁnement and all
further calculations were carried out using SHELXL-97 [25]. The hydrogen
atoms have been included in calculated positions and treated as riding atoms
using the SHELXL default parameters. All non-H atoms were reﬁned
anisotropically, using weighted full-matrix least-square on F2. All residual
electron densities greater than 1 e A˚)3 are observed around the Ru4 core
and PF6 anions. The ﬁnal ﬂack parameter was 0.49(8), thus suggesting a
racemically twinned crystal, however twin reﬁnement did not improve the
resolution. Graphical representations were made using ORTEP-32 [26].
Crystallographic details are summarised in Table 3.
CCDC 640690 contains the supplementary crystallographic data for
this paper. These data can be obtained free of charge from The Cambridge
Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif.
Cell Culture
Human A2780 and A2780cisR ovarian carcinoma cell lines were
obtained from the European Centre of Cell Cultures (ECACC, Porton
down, Salisbury, UK). All other cell culture reagents were obtained from
Gibco-BRL, Basel, Switzerland. The cells were routinely grown in RPMI
1640 medium containing 10% foetal calf serum (FCS) and antibiotics at
37 C and 6% CO2. For the MTT tests, the cells were seeded in 96-well
plates (Costar, Integra Biosciences, Cambridge, MA, USA) as monolayers
for 24 h in complete medium with 10% FCS, then fresh complete medium
with 5% FCS was added together with the drugs, and culture was continued
for another 72 h. The test (see below) was performed for the last 2 h without
changing the culture medium.
Determination of Cell Viability
The compounds were dissolved directly in culture medium to
the required concentration. Cell viability was determined using the MTT
assay which allows the quantiﬁcation of the mitochondrial activity in
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metabolically active cells. Following drug exposure, MTT (ﬁnal concentra-
tion 0.2 mg/mL) was added to the cells for 2 h, then the culture medium was
aspirated and the violet formazan precipitate dissolved in 0.1 N HCl in
2-propanol. The optical density, which is directly proportional to number of
surviving cells, was quantiﬁed at 540 nm using a multiwell plate reader
(iEMS Reader MF, Labsystems, US) and the percentage of surviving cells
was calculated from the absorbance of untreated control cells. The IC50
values for the inhibition of cell viability were determined by ﬁtting the plot
of the percentage of surviving cells against the drug concentration using a
sigmoidal function (OriginPro).
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